COMMUNIQUÉS West-GlobeNewswire

AshtonManual.org Launches as the Definitive Resource for Safe, Evidence-Based Benzodiazepine Tapering
27/02/2026
New Educational Platform Brings the Gold Standard of Benzodiazepine Withdrawal Guidance to Patients and Families, Backed by the Clinical Expertise of Dr. Mark Leeds, D.O. Fort Lauderdale, FL, Feb. 27, 2026 (GLOBE [...]
Disclosure of a transparency notification from AOC Pharma S.à r.l.
27/02/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
27/02/2026
Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS (Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNS Preparing protocol resubmission to incorporate FDA guidance [...]
Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States
27/02/2026
Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States Irving, Texas, USA – February 27, 2026 – Atos , a global leader in AI-powered digital transformation, today [...]
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
27/02/2026
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA [...]
Exceptional Clinical Trial Volunteers Presented National Citizen Scientist Awards for Research Efforts
27/02/2026
The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) [...]
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
27/02/2026
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term [...]
The Standard Process Brand Evolution Elevates Awareness of Whole Food Nutrition
27/02/2026
The company’s 97-year commitment to restore nutritional integrity as the foundation of health A Media Snippet accompanying this announcement is available by clicking on this link. PALMYRA, Wis., Feb. 27, 2026 (GLOBE [...]
Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
27/02/2026
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
27/02/2026
CRANFORD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
27/02/2026
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South [...]
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
27/02/2026
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“ [...]
MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations
27/02/2026
TOKYO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the Nasdaq Capital Market: NASDAQ: MRM) announced that the Master [...]
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27/02/2026
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple [...]
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
27/02/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with [...]
Nkarta to Participate in March Investor Conferences
27/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
27/02/2026
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry
27/02/2026
MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today [...]
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
27/02/2026
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement [...]

Pages